Form 4: IGM Biosciences Director, Kathleen Behrens, Reports Acquisition of Common Stock

Director Kathleen Behrens reports acquiring 1,471 shares of IGM Biosciences common stock through fully vested restricted stock units.

Summary

• On March 31, 2025, Kathleen Behrens, a director of IGM Biosciences, acquired 1,471 shares of common stock.
• The acquisition was through fully vested restricted stock units (RSUs), each representing a contingent right to receive one share of IGM Biosciences common stock.
• The RSUs were acquired at a price of $0, reflecting payment of a quarterly retainer in common stock pursuant to the Issuer's Outside Director Compensation Policy.
• Following the transaction, Behrens directly owns 20,751 shares of common stock.
• Behrens also indirectly owns 330,700 shares through the KBW 2005 Trust, 29,807 shares through the Non-Exempt Trust for Patrick R. Wilsey, and 29,806 shares through the Non-Exempt Trust for Shannon K. Wilsey, for which she serves as Trustee.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine transaction. Director acquiring shares can be seen as a slightly positive sign, but it's part of a compensation plan.

Positives

• The acquisition of shares by a director can be seen as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's continued investment in the company.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

IGM Biosciences, Kathleen Behrens, Form 4, Director, Common Stock, Restricted Stock Units, Beneficial Ownership, Acquisition